Bee venom may boost Parkinson’s treatment

Bee venom may enhance the effectiveness of standard Parkinson’s disease treatment and improve motor and cognitive function, according to a study by researchers at the University of Guadalajara in Mexico.

Experiments in mice found that combining freeze-dried bee venom with levodopa/carbidopa produced greater behavioral improvements than standard treatment alone, although further research is needed to clarify the biological mechanisms involved.

Parkinson’s disease is a neurodegenerative disorder caused by the loss of dopamine-producing neurons in the brain. This loss leads to motor symptoms such as tremors, as well as declines in cognitive and mental abilities.

Although current treatments—particularly levodopa combined with carbidopa—help alleviate symptoms by compensating for dopamine deficiency and improving motor function, their effectiveness may decline with long-term use. Patients may also develop troubling side effects, including motor fluctuations and involuntary movements. These challenges have prompted researchers to explore adjunctive therapies that could enhance the effects of standard treatment while reducing its complications.

Against this backdrop, a research team from the University of Guadalajara in Mexico investigated the potential use of bee venom as an adjunctive treatment. Their approach was based on the venom’s biologically active compounds, including melittin, phospholipase A2 and apamin. Previous studies have suggested that these compounds possess anti-inflammatory and antioxidant properties, as well as potentially beneficial effects on the nervous system.

The study found that bee venom may enhance the effectiveness of standard Parkinson’s disease treatment. Experiments in mice showed significant improvements in motor and cognitive performance when bee venom was combined with levodopa/carbidopa, pointing to a potentially promising avenue for the development of adjunctive therapies for the chronic neurological disorder.

To test their hypothesis, the researchers used an established animal model in neuroscience research. Male CD-1 mice were injected with a chemical known as 6-hydroxydopamine, which damages dopamine-producing cells and thereby mimics aspects of the neuronal damage observed in the brains of people with Parkinson’s disease.

The mice were then divided into four groups: a healthy control group that did not develop the disease; an untreated group with induced Parkinsonian damage; a group receiving standard treatment with levodopa/carbidopa; and a fourth group receiving the standard treatment in combination with freeze-dried bee venom.

Treatment continued for 18 days, from day 13 to day 30 after the lesion was induced. All the mice then underwent a series of motor and cognitive assessments, including the cylinder test, the stepping test, the novel object recognition test and the lateral corridor test.

The results showed that mice receiving bee venom alongside standard treatment achieved notable improvements in several areas compared with the other groups.

In terms of motor function, these mice maintained better coordination in their forelimbs and displayed fewer stepping deficits, indicating improved motor performance compared with animals that received standard treatment alone.

The cognitive findings were also significant. In memory tests, mice treated with bee venom retained their ability to recognize novel objects, while the other groups continued to show cognitive impairment. The combined-treatment group also demonstrated the strongest improvement in lateralized motor behavior during the lateral corridor test.

However, the researchers acknowledged important limitations to the study. Their work focused exclusively on behavioral outcomes and did not directly assess the survival of dopamine-producing neurons or measure molecular markers of inflammation and oxidative stress that could help explain the biological mechanisms underlying the observed improvements.

For this reason, the study’s lead author, Professor Alma Karen Lomelí-Libé, said the findings point to promising behavioral benefits from bee venom as an adjunctive therapy, while emphasizing the urgent need for further research to understand the precise mechanisms through which the venom may exert its effects.

Although a long path remains before such an approach could be considered for use in humans, the findings open the door to a potentially promising area of research into new adjunctive treatments—approaches that could ultimately make a meaningful difference in the lives of millions of people living with Parkinson’s disease worldwide, particularly those whose response to standard therapy declines over time or who experience treatment-related side effects.